Commercialization readiness of visual biofeedback to reduce head motion during MRI scans
Commercialization readiness of visual biofeedback to reduce head motion during MRI scans
批准号:
10532740
负责人:
Ken Bruener
金额:
$113.69万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-12-01 至 2024-11-30
关键词:
AdultAgeAmericanAnesthesia proceduresAwardBackBehavioralBiofeedbackBrain imagingCategoriesChildChildhoodClient satisfactionClinicalClinical ResearchCodeComputer softwareConsciousCurrent Procedural TerminologyCurrent Procedural Terminology CodesDataDevelopmentElderlyEmerging TechnologiesEnsureFaceFeedbackFeedsFunctional Magnetic Resonance ImagingGoalsGrantHeadHealthHospitalsImageInstitutionLettersMRI ScansMagnetic Resonance ImagingMarket ResearchMarketingMeasurementMedicalMethodsMonitorMotionMovementParticipantPatientsPhysiciansPredispositionPreparationPriceProtocols documentationQuestionnairesRadiationRelaxationResearchResearch SubjectsResolutionRiskRobin birdSafetyScanningSecureSedation procedureSiteSocietiesSystemTechnologyTestingTimeTrainingTranslatingUnited StatesUnited States Centers for Medicare and Medicaid ServicesVisualWorkawakebasebiobehaviorbrain magnetic resonance imagingclinical careclinical practicecombatcommercializationcommercialization readinesscostcost estimatediagnostic toolexperiencehigh resolution imagingimprovedinterestnon-invasive monitorpreventprice listsprogramssoftware developmentsuccessusabilityvisual feedbackwasting
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Abstract/Summary
The goal of this CRP application is to successfully commercialize a brain MRI technology that feeds
back head motion measurements derived from our Framewise Integrated Real-Time MRI Monitoring (FIRMM)
software to MRI scan participants in order to reduce head motion via behavioral training. Because MRI
scanning produces high-resolution images and does not expose patients to radiation, it has become an
immensely valuable diagnostic tool, particularly for imaging the brain. Last year, in the United States alone,
there were over 8 million brain MRIs, costing an estimated $20-30 billion. Unfortunately, brain MRIs are limited
by the fact that head motion during the scan can cause the resulting images to be suboptimal or even
unusable. An estimated 20% of all brain MRIs are ruined by motion, wasting $2-4 billion annually. Currently,
there are two predominant strategies to combat head motion: repeat scanning and anesthesia, both of which
are inadequate. Repeat scanning, which consists of acquiring extra images (to ensure enough usable ones
were acquired), increases scanning time and cost, and can result in too few usable images or unnecessary
extra images. Anesthesia, which is given to patients who are likely to move (such as young children), presents
a serious safety risk and is sometimes administered unnecessarily (i.e. the patient could hold still without
anesthesia). Anesthesia is never an option for functional MRI (fMRI), which requires participants to be awake.
The software-based FIRMM-biofeedback solution we developed uses MR images (as they are being
collected) to compute a patient’s head motion in real time during an MRI scan. The availability of real time
motion information enables more informed anesthesia use and reduce excess scanning, making these
methods safer and more efficient. Armed with real time motion information, scan operators will know exactly
how many usable images have been acquired, preventing the acquisition of too many or too few extra images.
Additionally, providing physicians with quantitative information about patient motion will allow them to make an
informed decision regarding anesthesia, preventing unnecessary sedation.
FIRMM technology provides a completely new biobehavioral method for combating head motion:
patient biofeedback. FIRMM can translate the head motion information into age-appropriate, visual
biofeedback for the scan participant. By providing feedback to patients and research subjects, the FIRMM-
biofeedback technology helps both pediatric and adult patients remain more still, improving image quality. The
proposed research focuses on completing late-stage development for FIRMM-biofeedback getting ready for
commercialization, by building a marketing and reimbursement strategy. The FIRMM-biofeedback technology
provides patients and research subjects with real time head motion information, with the goal of making MR
scans safer, faster, more enjoyable and less expensive.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Framewise Integrated Real-Time MRI Monitoring (FIRMM) software commercialization readiness for clinical care
-
批准号:10697965
-
项目类别:
-
资助金额:$106.28万
-
财政年份:2023
-
负责人:Ken Bruener
-
依托单位:
Behavioral feedback and rewards for improving functional brain mapping in presurgical pediatric patients
-
批准号:10546990
-
项目类别:
-
资助金额:$49.98万
-
财政年份:2022
-
负责人:Ken Bruener
-
依托单位:
Behavioral feedback and rewards for improving functional brain mapping in presurgical pediatric patients
-
批准号:10707227
-
项目类别:
-
资助金额:$19.88万
-
财政年份:2022
-
负责人:Ken Bruener
-
依托单位:
Commercialization readiness of visual biofeedback to reduce head motion during MRI scans
-
批准号:10382713
-
项目类别:
-
资助金额:$113.69万
-
财政年份:2021
-
负责人:Ken Bruener
-
依托单位:
Visual biofeedback to reduce head motion during MRI scans
-
批准号:10199977
-
项目类别:
-
资助金额:$151.92万
-
财政年份:2019
-
负责人:Ken Bruener
-
依托单位:
Visual biofeedback to reduce head motion during MRI scans
-
批准号:10437644
-
项目类别:
-
资助金额:$182.53万
-
财政年份:2019
-
负责人:Ken Bruener
-
依托单位:
Visual biofeedback to reduce head motion during MRI scans
-
批准号:10442332
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2019
-
负责人:Ken Bruener
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: